Research programme: nitric oxide-based COX-2 inhibitors and NSAIDs - NitroMed

Drug Profile

Research programme: nitric oxide-based COX-2 inhibitors and NSAIDs - NitroMed

Alternative Names: NMI 150; NMI 153; NMI 159; NMI 161; NMI 172; NMI 377; NMI-1182

Latest Information Update: 19 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NitroMed
  • Class Naphthalenes; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Pain

Most Recent Events

  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
  • 20 Sep 2005 Data presented at the 230th National Meeting of the American Chemical Society (230th ACS-2005) have been added to the Inflammation pharmacodynamics section
  • 31 Dec 2004 Merck & Co. has terminated its licence for nitric oxide-based COX-2 inhibitors and NSAIDs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top